138 related articles for article (PubMed ID: 35689843)
1. Inhibition of STAT3 reverses Taxol-resistance in ovarian cancer by down-regulating G6PD expression in vitro.
Sheng H; Feng Q; Quan Q; Sheng X; Zhang P
Biochem Biophys Res Commun; 2022 Aug; 617(Pt 2):62-68. PubMed ID: 35689843
[TBL] [Abstract][Full Text] [Related]
2. Targeting G6PD reverses paclitaxel resistance in ovarian cancer by suppressing GSTP1.
Feng Q; Li X; Sun W; Sun M; Li Z; Sheng H; Xie F; Zhang S; Shan C
Biochem Pharmacol; 2020 Aug; 178():114092. PubMed ID: 32535103
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of IL-6/STAT3 axis and targeting Axl and Tyro3 receptor tyrosine kinases by apigenin circumvent taxol resistance in ovarian cancer cells.
Suh YA; Jo SY; Lee HY; Lee C
Int J Oncol; 2015 Mar; 46(3):1405-11. PubMed ID: 25544427
[TBL] [Abstract][Full Text] [Related]
4. Insulin-like growth factor 2 silencing restores taxol sensitivity in drug resistant ovarian cancer.
Brouwer-Visser J; Lee J; McCullagh K; Cossio MJ; Wang Y; Huang GS
PLoS One; 2014; 9(6):e100165. PubMed ID: 24932685
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of Tyro3 receptor tyrosine kinase leads to the acquisition of taxol resistance in ovarian cancer cells.
Lee C
Mol Med Rep; 2015 Jul; 12(1):1485-92. PubMed ID: 25815442
[TBL] [Abstract][Full Text] [Related]
6. TIMP-2 regulates proliferation, invasion and STAT3-mediated cancer stem cell-dependent chemoresistance in ovarian cancer cells.
Escalona RM; Bilandzic M; Western P; Kadife E; Kannourakis G; Findlay JK; Ahmed N
BMC Cancer; 2020 Oct; 20(1):960. PubMed ID: 33023532
[TBL] [Abstract][Full Text] [Related]
7. Role of GPX4 inhibition-mediated ferroptosis in the chemoresistance of ovarian cancer to Taxol in vitro.
Feng Q; Hao S; Fang P; Zhang P; Sheng X
Mol Biol Rep; 2023 Dec; 50(12):10189-10198. PubMed ID: 37924448
[TBL] [Abstract][Full Text] [Related]
8. G6PD downregulation triggered growth inhibition and induced apoptosis by regulating STAT3 signaling pathway in esophageal squamous cell carcinoma.
Wang X; Liu H; Zhang X; Li X; Gu H; Zhang H; Fan R
Tumour Biol; 2016 Jan; 37(1):781-9. PubMed ID: 26250461
[TBL] [Abstract][Full Text] [Related]
9. ID1 promotes hepatocellular carcinoma proliferation and confers chemoresistance to oxaliplatin by activating pentose phosphate pathway.
Yin X; Tang B; Li JH; Wang Y; Zhang L; Xie XY; Zhang BH; Qiu SJ; Wu WZ; Ren ZG
J Exp Clin Cancer Res; 2017 Nov; 36(1):166. PubMed ID: 29169374
[TBL] [Abstract][Full Text] [Related]
10. [Expression and significance of heparin binding-epidermal growth factor-like growth factor in paclitaxel-resistant ovarian cancer].
Tang X; Lu M; Li C; Deng S; Li M
Zhonghua Fu Chan Ke Za Zhi; 2014 Jul; 49(7):517-22. PubMed ID: 25327734
[TBL] [Abstract][Full Text] [Related]
11. Targeting epidermal growth factor receptor in paclitaxel-resistant human breast and lung cancer cells with upregulated glucose-6-phosphate dehydrogenase.
Min HY; Lee HJ; Suh YA; Pei H; Kwon H; Jang HJ; Yun HJ; Moon HG; Lee HY
Br J Cancer; 2022 Sep; 127(4):661-674. PubMed ID: 35597872
[TBL] [Abstract][Full Text] [Related]
12. Glucose-6-phosphate dehydrogenase promotes the proliferation and migration of lung adenocarcinoma cells via the STAT3 signaling pathway.
Wu W; Yu F; Yu N; Zhu Y; Wu W; Gao P; Chen C
J Mol Histol; 2022 Apr; 53(2):215-225. PubMed ID: 35028787
[TBL] [Abstract][Full Text] [Related]
13. CD109 Promotes Drug Resistance in A2780 Ovarian Cancer Cells by Regulating the STAT3-NOTCH1 Signaling Axis.
Kim JS; Shin MJ; Lee SY; Kim DK; Choi KU; Suh DS; Kim D; Kim JH
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373457
[TBL] [Abstract][Full Text] [Related]
14. Differential microRNA expression signatures and cell type-specific association with Taxol resistance in ovarian cancer cells.
Kim YW; Kim EY; Jeon D; Liu JL; Kim HS; Choi JW; Ahn WS
Drug Des Devel Ther; 2014; 8():293-314. PubMed ID: 24591819
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA-503-5p Inhibits the CD97-Mediated JAK2/STAT3 Pathway in Metastatic or Paclitaxel-Resistant Ovarian Cancer Cells.
Park GB; Kim D
Neoplasia; 2019 Feb; 21(2):206-215. PubMed ID: 30622051
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of miR-138-5p Sensitizes Taxol-Resistant Epithelial Ovarian Cancer Cells through Targeting Cyclin-Dependent Kinase 6.
Liang M; Li Q; Shi S; Tian YN; Feng Y; Yang Y; Dong M; Zhang J; He J
Gynecol Obstet Invest; 2021; 86(6):533-541. PubMed ID: 34818258
[TBL] [Abstract][Full Text] [Related]
17. Variant G6PD levels promote tumor cell proliferation or apoptosis via the STAT3/5 pathway in the human melanoma xenograft mouse model.
Hu T; Zhang C; Tang Q; Su Y; Li B; Chen L; Zhang Z; Cai T; Zhu Y
BMC Cancer; 2013 May; 13():251. PubMed ID: 23693134
[TBL] [Abstract][Full Text] [Related]
18. Glucose-6-phosphate dehydrogenase: a therapeutic target for ovarian cancer.
Wang C; Yu C; Chang H; Song J; Zhang S; Zhao J; Wang J; Wang T; Qi Q; Shan C
Expert Opin Ther Targets; 2023; 27(8):733-743. PubMed ID: 37571851
[TBL] [Abstract][Full Text] [Related]
19. [Reverse of the resistance to paclitaxel of the heparin binding-epidermal growth factor-like growth factor inhibitor in ovarian cancer].
Tang XH; Lu MS; Deng S; Li M
Zhonghua Fu Chan Ke Za Zhi; 2017 Feb; 52(2):110-115. PubMed ID: 28253574
[No Abstract] [Full Text] [Related]
20. Signal transducers and activators of transcription 3 pathway activation in drug-resistant ovarian cancer.
Duan Z; Foster R; Bell DA; Mahoney J; Wolak K; Vaidya A; Hampel C; Lee H; Seiden MV
Clin Cancer Res; 2006 Sep; 12(17):5055-63. PubMed ID: 16951221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
